PMDA drug package insert
アビラテロン酢酸エステル錠250mg「サンド」
PMDA Prescription drug · サンド株式会社 · package insert Aug 17, 2026
Key facts
| Brand names | アビラテロン酢酸エステル錠250mg「サンド」, アビラテロン酢酸エステル錠500mg「サンド」 |
|---|---|
| Nonproprietary names | アビラテロン酢酸エステル |
| Companies | 製造販売／サンド株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 前立腺癌治療剤（CYP17阻害剤） |
| Therapeutic category codes | 874291 |
| YJ codes | 4291033F1075, 42910G0F1041 |
| Approval numbers | 30500AMX00210000, 30800AMX00265000 |
| Package insert edition | 第2版 |
| Package insert date | Aug 17, 2026 |
| PMDA document key | 270428_4291033F1075_1 |
| PMDA company code | 270428 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: